News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Scancell Release: SCIB1 Immunobody DNA Vaccine Phase I Trial Commences


6/15/2010 6:59:45 AM

NOTTINGHAM, UK--(BUSINESS WIRE)--Scancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer vaccines, today announces the enrolment and treatment of the first patient in its multicentre Phase I clinical trial of SCIB1, its DNA ImmunoBody® vaccine being developed for the treatment of melanoma. The trial will evaluate the safety and tolerability of SCIB1 in patients with late stage melanoma.

Read at BioSpace.com


comments powered by Disqus
   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES